Influx Healthtech Limited
Bookbuilding IPO · NSE
- Price band
- ₹91 - ₹96
- Lot size
- 1,200 shares
- Issue amount
- ₹58.57 cr
- Total subscription
- 187.32×
- Opens
- 18 Jun 2025
- Closes
- 20 Jun 2025
- Allotment
- 23 Jun 2025
- Listing
- 25 Jun 2025
Offer at a glance
Issue overview
- Issue size
- 61,00,800 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,09,200
- Fresh issue
- ₹48 cr
- Offer for sale
- ₹10.56 cr
- Registrar
- Maashitla Securities Private Limited
- Listing exchange
- NSE
- Maximum investment
- ₹1,15,200
- Issue type
- Bookbuilding IPO
- Shares before issue
- 1,81,50,000
- Shares after issue
- 2,31,50,400
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 1,200 | ₹1,15,200 |
| HNI | 2 | 2,400 | ₹2,30,400 |
Share reservation
Subscription & GMP
Subscription by category
Missing multiples are calculated from bids and offered shares when available.
GMP history
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | — | 99 |
| NIB | — | 21,204 |
| RETAIL | — | 1,99,035 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 11.13 | 1,534.26 |
| RETAIL | 19.48 | 2,292.88 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 7.36 | 6.13 | 3.96 |
| ROE | 36.98 | 48.85 | 61.76 |
| ROCE | 49.17 | 65.58 | 78.6 |
| RONW | 36.98 | 36.98 | 61.76 |
| PRE IPO(PE) | 13.04 | 0 | 0 |
| POST IPO(PE) | 16.63 | 0 | 0 |
Values and labels as reported in the issue data.
Company information
Company profile
Influx Healthtech Limited, established in September 2020, is a healthcare-focused company that provides contract manufacturing services. It operates as a trusted CDMO (Contract Development and Manufacturing Organization), serving clients across various sectors. The company runs three manufacturing units located in Thane, Maharashtra, with facility sizes of 9,676 sq. ft., 13,000 sq. ft., and 14,000 sq. ft. Its product range includes tablets, capsules, powders, liquid orals, softgels, lozenges, jellies, gummies, oral dispersible films, effervescent tablets, liquid-fill capsules, candies, gym and sports supplements, as well as skincare, body care, hair care, beard care products, face masks, and soaps. It also manufactures ayurvedic and herbal formulations, veterinary feed supplements, and homecare products. The company supports nutraceutical and cosmetic businesses by handling the entire process from product development to manufacturing and regulatory assistance, allowing clients to concentrate on formulation and market launch. As of June 11, 2025, Influx Healthtech Limited employs 163 full-time staff members.
Strengths
- Wide Product Range – Offers products in pharma, nutraceuticals, and cosmetics
- Trusted Client Base – Strong relationships with well-known health and wellness brands
- Strong Quality Control – Follows GMP, FSSAI, and other standards with strict quality checks
Risk factors
- High Competition – Competes with big CDMO players like Jubilant and Divi’s Labs
- Raw Material Price Fluctuations – Changing input costs can reduce profit margins
- Dependence on Key Clients – Losing major customers could impact business stability.
Promoters
Mr. Munir Abdul Ganee Chandniwala
Mrs. Shirin Munir Ahmed Chandniwala
Mr. Abdul Ganee Abdul Rasul Chandniwala
Registrar & documents
Lead manager
Rarever Financial Advisors Private Limited
Registrar & contacts
Maashitla Securities Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
109, Ghanshyam Enclave Premises Co-op Soc Plot No. 856, Laljipada Kandivali West, Mumbai, Maharashtra
+91 7045997809
[email protected]Company website ↗Understanding INFLUX IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.